Trial intelligence / Profile preview

BL-M08D1 in recurrent or metastatic head and neck squamous cell carcinoma and other solid tumors

NCT07788950Phase 2Not yet recruiting

Sponsor
Biokin Pharmaceutical
Start
Sep 2026
Primary completion
Dec 2028
Countries
1
01

Overview

A Phase 2 trial of BL-M08D1 in head and neck squamous cell carcinoma (HNSCC), solid tumor, sponsored by Biokin Pharmaceutical. Planned start Sep 2026; status: not yet recruiting.

02

Drugs

BL-M08D1
03

Conditions

head and neck squamous cell carcinoma (HNSCC)solid tumor

Beyond the preview

Go deeper on NCT07788950.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07788950.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call